Role of angiogenesis in the pathogenesis of cancer

Cancer Treatment Reviews

Volumn 38, Issue 7, 2012, Pages 825-833

  Hoff, Paulo M ^a   Machado, Karime Kalil ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Angiogenesis; Antiangiogenesis; Cancer; Placental growth factor; Vascular endothelial growth factor; VEGF A; VEGF B

Indexed keywords

BEVACIZUMAB; BRIVANIB; CELECOXIB; ERLOTINIB; GEFITINIB; LAPATINIB; LENALIDOMIDE; MESSENGER RNA; NECITUMUMAB; NERATINIB; NIMOTUZUMAB; PANITUMUMAB; PAZOPANIB; RAMUCIRUMAB; REGORAFENIB; SORAFENIB; SUNITINIB; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB; ZALUTUMUMAB;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; BASEMENT MEMBRANE; BINDING AFFINITY; BREAST CANCER; CANCER CELL CULTURE; CARCINOGENESIS; CELL INFILTRATION; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; DISEASE COURSE; EXTRACELLULAR MATRIX; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER CARCINOMA; LUNG NON SMALL CELL CANCER; MACROPHAGE; MEDULLARY CARCINOMA; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS TUMOR; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STOMACH ADENOCARCINOMA; THYROID CANCER; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

EID: 84865408903     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.04.006     Document Type: Review

References (104)

1. Skalak T.C. Angiogenesis and microvascular remodeling: a brief history and future roadmap. Microcirculation 2005, 12:47-58.
2. Goldmann E. The growth of malignant disease in man and the lower animals, with special reference to the vascular system. Proc R Soc Med 1908, 1:1-13. (Surg Sect).
3. Clark E.R., Clark E.L. Microscopic observations on the growth of blood capillaries in the living mammal. Am J Anat 1939, 64:251-301.
4. Clark E.R., Hitschler W.J., Kirby-Smith H.T., Rex R.O., Smith J.H. General observations on the ingrowth of new blood vessels into standardized chambers in the rabbit's ear, and the subsequent changes in the newly grown vessels over a period of months. Anat Rec 1931, 50:129-167.
5. Folkman J., Merler E., Abernathy C., Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133:275-288.
6. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002, 29(Suppl. 16):15-18.
7. Ferrara N., Henzel W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989, 161:851-858.
8. Plouet J., Schilling J., Gospodarowicz D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT-20 cells. EMBO J 1989, 8:3801-3806.
9. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
10. Keck P.J., Hauser S.D., Krivi G., et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989, 246:1309-1312.
11. Conn G., Bayne M.L., Soderman D.D., et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc Natl Acad Sci U S A 1990, 87:2628-2632.
12. Folkman J., Shing Y. Angiogenesis. J Biol Chem 1992, 267:10931-10934.
13. Folkman J. Fundamental concepts of the angiogenesis process. Curr Mol Med 2003, 3:643-651.
14. Chung A.S., Lee J., Ferrara N. Targeting the tumour vascalature: insights from physiological angiogenesis. Nat Cancer Rev 2010, 10:505-514.
15. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl. 1):2-10.
16. Ribatti D., Vacca A., Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999, 1:293-302.
17. Baluk P., Hashizume H., McDonald D.M. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev 2005, 15:102-111.
18. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
19. Maglione D., Guerriero V., Viglietto G., Delli-Bovi P., Persico M.G. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A 1991, 88:9267-9271.
20. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008, 11:215-221.
21. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
22. Cao Y. Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal 2009, 2:re1.
23. Levy N.S., Chung S., Furneaux H., Levy A.P. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 1998, 273:6417-6423.
24. Mizukami Y., Kohgo Y., Chung D.C. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007, 13:5670-5674.
25. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
26. von Marschall Z., Scholz A., Cramer T., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95:437-448.
27. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
28. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005, 69(Suppl. 3):11-16.
29. Shibuya M. Tyrosine kinase receptor Flt/VEGFR family: its characterization related to angiogenesis and cancer. Genes Cancer 2010, 1:1119-1123.
30. Waltenberger J., Claesson-Welsh L., Siegbahn A., Shibuya M., Heldin C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994, 269:26988-26995.
31. Shalaby F., Rossant J., Yamaguchi T.P., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995, 376:62-66.
32. Terman B.I., Dougher-Vermazen M., Carrion M.E., et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992, 187:1579-1586.
33. Fan F., Wey J.S., McCarty M.F., et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005, 24:2647-2653.
34. Ghanem M.A., van Steenbrugge G.J., Sudaryo M.K., Mathoera R.B., Nijman J.M., van der Kwast T.H. Expression and prognostic relevance of vascular endothelial growth factor (VEGF) and its receptor (FLT-1) in nephroblastoma. J Clin Pathol 2003, 56:107-113.
35. Soker S., Takashima S., Miao H.Q., Neufeld G., Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998, 92:735-745.
36. Tam B.Y., Wei K., Rudge J.S., et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006, 12:793-800.
37. Olofsson B., Korpelainen E., Pepper M.S., et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci U S A 1998, 95:11709-11714.
38. Park J.E., Chen H.H., Winer J., Houck K.A., Ferrara N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J Biol Chem 1994, 269:25646-25654.
39. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575-583.
40. Zhang F., Tang Z., Hou X., et al. VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A 2009, 106:6152-6157.
41. Makinen T., Olofsson B., Karpanen T., et al. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J Biol Chem 1999, 274:21217-21222.
42. Li Y., Zhang F., Nagai N., et al. VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 2008, 118:913-923.
43. Yang W., Ahn H., Hinrichs M., Torry R.J., Torry D.S. Evidence of a novel isoform of placenta growth factor (PlGF-4) expressed in human trophoblast and endothelial cells. J Reprod Immunol 2003, 60:53-60.
44. Escudero-Esparza A., Martin T.A., Davies M.L., Jiang W.G. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. Cancer Genomics Proteomics 2009, 6:239-246.
45. Yao J., Wu X., Zhuang G., et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A 2011, 108:11590-11595.
46. Fischer C., Jonckx B., Mazzone M., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
47. Bais C., Wu X., Yao J., et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010, 141:166-177.
48. Kopetz S., Hoff P.M., Morris J.S., et al. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010, 28:453-459.
49. Batchelor T.T., Sorensen A.G., di Tomaso E., et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
50. Willett C.G., Duda D.G., di Tomaso E., et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
51. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
52. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and doselimiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
53. Zhu A.X., Sahani D.V., Duda D.G., et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
54. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997, 277:48-50.
55. Oliner J., Min H., Leal J., et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell 2004, 6:507-516.
56. Valtola R., Salven P., Heikkilä P., et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999, 154:1381-1390.
57. Das S., Ladell D.S., Podgrabinska S., et al. Vascular endothelial growth factor-C induces lymphangitic carcinomatosis, an extremely aggressive form of lung metastases. Cancer Res 2010, 70:1814-1824.
58. Jubb A.M., Miller K.D., Rugo H.S., et al. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res 2011, 17:372-381.
59. Khromova N., Kopnin P., Rybko V., Kopnin B.P. Downregulation of VEGF-C expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012, 31:1389-1397.
60. Bolos V., Grego-Bessa J., de la Pompa J.L. Notch signaling in development and cancer. Endocr Rev 2007, 28:339-363.
61. Kuhnert F., Kirshner J.R., Thurston G. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 2011, 3:20.
62. Dufraine J., Funahashi Y., Kitajewski J. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008, 27:5132-5137.
63. Hofmann J.J., Iruela-Arispe M.L. Notch signaling in blood vessels: who is talking to whom about what?. Circ Res 2007, 100:1556-1568.
64. Iso T., Hamamori Y., Kedes L. Notch signaling in vascular development. Arterioscler Thromb Vasc Biol 2003, 23:543-553.
65. Li J.L., Sainson R.C., Oon C.E., et al. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Cancer Res 2011, 71:6073-6083.
66. Rege T.A., Fears C.Y., Gladson C.L. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy. Neuro Oncol 2005, 7:106-121.
67. Nyberg P., Xie L., Kalluri R. Endogenous inhibitors of angiogenesis. Cancer Res 2005, 65:3967-3979.
68. Joe Y.A., Hong Y.K., Chung D.S., et al. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int J Cancer 1999, 82:694-699.
69. Ma H.I., Lin S.Z., Chiang Y.H., et al. Intratumoral gene therapy of malignant brain tumor in a rat model with angiostatin delivered by adeno-associated viral (AAV) vector. Gene Ther 2002, 9:2-11.
70. Strik H.M., Schluesener H.J., Seid K., Meyermann R., Deininger M.H. Localization of endostatin in rat and human gliomas. Cancer 2001, 91:1013-1019.
71. Schmidt N.O., Ziu M., Carrabba G., et al. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clin Cancer Res 2004, 10:1255-1262.
72. Kazerounian S., Yee K.O., Lawler J. Thrombospondins in cancer. Cell Mol Life Sci 2008, 65:700-712.
73. Giuriato S., Ryeom S., Fan A.C., et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci U S A 2006, 103:16266-16271.
74. Ebbinghaus S., Hussain M., Tannir N., et al. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 2007, 13(22 Pt. 1):6689-6695.
75. Sato Y., Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol 2007, 27:37-41.
76. Hosaka T., Kimura H., Heishi T., et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol 2009, 175:430-439.
77. Avastin (bevacizumab) [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2004.
78. Erbitux (cetuximab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; Indianapolis, IN: Eli Lilly and Company; 2004.
79. Vectibix (panitumumab) [prescribing information]. Thousand Oaks, CA: Amgen Inc.; 2006.
80. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99:11393-11398.
81. Tew W.P., Gordon M., Murren J., et al. Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors. Clin Cancer Res 2010, 16:358-366.
82. Van Cutsem E., Tabernero J., Lakomy R., et al. Intravenous Aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): results of a multinational Phase III trial (EFC10262-VELOUR) [abstract O-0024]. Ann Oncol 2011, 22(s5).
83. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer [published online ahead of print December 19, 2011]. J Clin Oncol. doi:10.1200/JCO.2010.34.3178.
84. Amgen. TRINOVA-1: a study of AMG 386 or placebo, in combination with weekly paclitaxel chemotherapy, as treatment for ovarian cancer, primary peritoneal cancer and fallopian tube cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2011 Nov 13]. Available from: NLM Identifier: NCT01204749. http://www.clinicaltrials.gov/show/NCT01204749.
85. Amgen. TRINOVA-3: a study of AMG 386 or AMG 386 placebo in combination with paclitaxel and carboplatin to treat ovarian cancer. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 - [cited 2011 Nov 13]. Available from: NLM Identifier: NCT01493505. http://www.clinicaltrials.gov/show/NCT01493505.
86. Li X., Liu X., Wang J., et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 2003, 23:2481-2487.
87. Kotoh T., Dhar D.K., Masunaga R., et al. Antiangiogenic therapy of human esophageal cancers with thalidomide in nude mice. Surgery 1999, 125:536-544.
88. Myoung H., Hong S.D., Kim Y.Y., Hong S.P., Kim M.J. Evaluation of the anti-tumor and anti-angiogenic effect of paclitaxel and thalidomide on the xenotransplanted oral squamous cell carcinoma. Cancer Lett 2001, 163:191-200.
89. Ruddy J.M., Majumdar S.K. Antitumorigenic evaluation of thalidomide alone and in combination with cisplatin in DBA2/J mice. J Biomed Biotechnol 2002, 2:7-13.
90. Yaccoby S., Johnson C.L., Mahaffey S.C., Wezeman M.J., Barlogie B., Epstein J. Antimyeloma efficacy of thalidomide in the SCID-hu model. Blood 2002, 100:4162-4168.
91. Fujii T., Tachibana M., Dhar D.K., et al. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res 2003, 23:2405-2411.
92. Thalomid (thalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; 2006.
93. Revlimid (lenalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; 2005.
94. Raut C.P., Nawrocki S., Lashinger L.M., et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004, 3:1217-1224.
95. Bergers G., Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008, 8:592-603.
96. Lieu C.H., Tran H.T., Jiang Z., et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer [Abstract 3533]. J Clin Oncol 2011, 29(Suppl.):3533.
97. Loupakis F., Cremolini C., Fioravanti A., et al. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. Br J Cancer 2011, 104:1262-1269.
98. Ylä-Herttuala S., Rissanen T.T., Vajanto I., Hartikainen J. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 2007, 49(10):1015-1026.
99. Nexavar (sorafenib) [prescribing information]. Wayne, NJ: Bayer Healthcare Pharmaceuticals, Inc.; 2005.
100. Sutent (sunitinib malate) [prescribing information]. New York, NY: Pfizer Inc; 2006.
101. Votrient (pazopanib) [prescribing information] Research Triangle Park, NC: GlaxoSmithKline; 2009.
102. Tarceva (erlotinib) [prescribing information]. South San Francisco, CA: Genentech Inc; 2004.
103. Caprelsa (vandetanib) [prescribing information]. Wilmington, DE: Astra Zeneca.
104. Tykerb (lapatinib) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2007.